AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17394651 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) point of care testing
Number of subjects: 400
Study 17394651 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced communication skills training
Number of subjects: 400
Study 17394651 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CRP testing and communication skills training
Number of subjects: 400
Study 17394651 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 400
Study 17394651 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP testing
Number of subjects: 400
Study 17394651 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training
Number of subjects: 400
Study 15718402 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 1512
Study 15718402 — intervention group
Group type: EXPERIMENTAL
Intervention: Men and Women
Number of subjects: 1512
Study 12015695 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid (600 mg twice daily)
Number of subjects: 460
Study 12015695 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (1 g twice daily)
Number of subjects: 460
Study 10501557 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory oddball task
Number of subjects: 0
Study 10501557 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual oddball task
Number of subjects: 0
Study 10501557 — intervention group
Group type: EXPERIMENTAL
Intervention: Modality non-specific activations
Number of subjects: 0
Study 7596886 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketamine (10 mg/kg)
Number of subjects: 30
Study 7596886 — intervention group
Group type: COMPARATOR
Intervention: Placebo syrup
Number of subjects: 30
Study 2187344 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline solution amnioinfusion
Number of subjects: 100
Study 2187344 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 6253021 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar crispbread combined with wholemeal bread
Number of subjects: 6
Study 6253021 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread and soya beans
Number of subjects: 6
Study 6253021 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar crispbread with soya beans
Number of subjects: 6
Study 6253021 — intervention group
Group type: EXPERIMENTAL
Intervention: Soya beans with lentils
Number of subjects: 6
Study 6253021 — intervention group
Group type: COMPARATOR
Intervention: Porridge and cornflake breakfasts
Number of subjects: 6
Study 30885505 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromocolonoscopy (indigo carmine dye [0.2%])
Number of subjects: 741
Study 30885505 — intervention group
Group type: COMPARATOR
Intervention: Standard white light colonoscopy
Number of subjects: 741
Study 30885505 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromocolonoscopy
Number of subjects: 741
Study 28147433 — intervention group
Group type: EXPERIMENTAL
Intervention: Aftercare services including telephone follow-up or home visit, caregivers' education and training of social skills, for 20 months after hospital discharge.
Number of subjects: 120
Study 28147433 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 120
Study 28147433 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 28147433 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention from the MoH perspective
Number of subjects: 120
Study 26494370 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg/d)
Number of subjects: 15
Study 26494370 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg/d)
Number of subjects: 15
Study 26494370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 24127645 — intervention group
Group type: EXPERIMENTAL
Intervention: High-soy diet
Number of subjects: 82
Study 24127645 — intervention group
Group type: COMPARATOR
Intervention: Low-soy diet
Number of subjects: 82
Study 21411800 — intervention group
Group type: COMPARATOR
Intervention: Placebo loading dose followed by conivaptan continuous i.v. infusion using the ampul formulation (regimen 1)
Number of subjects: 121
Study 21411800 — intervention group
Group type: EXPERIMENTAL
Intervention: Conivaptan loading dose followed by continuous i.v. infusion using the ampul formulation (regimen 2)
Number of subjects: 121
Study 21411800 — intervention group
Group type: COMPARATOR
Intervention: Placebo loading dose followed by conivaptan continuous i.v. infusion using the premixed formulation (regimen 3)
Number of subjects: 121
Study 21411800 — intervention group
Group type: EXPERIMENTAL
Intervention: Conivaptan loading dose followed by continuous i.v. infusion using the premixed formulation (regimen 4)
Number of subjects: 121
Study 19643834 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand cycle interval training (8-12 weeks)
Number of subjects: 22
Study 17894831 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention (four educational sessions during year 1)
Number of subjects: 0
Study 17894831 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (four educational sessions during year 2)
Number of subjects: 0
Study 17894831 — intervention group
Group type: EXPERIMENTAL
Intervention: Families attending >= 2 sessions
Number of subjects: 0
Study 15531219 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals reporting long-term pain; 12.8 contacts per year to primary health care sector
Number of subjects: 22684
Study 15531219 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals reporting long-term pain; higher frequency of hospital admissions and in-hospital days
Number of subjects: 22684
Study 15531219 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pain)
Number of subjects: 22684
Study 11465987 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus-Continuous (BC-) group (3 mg base rate/h, 1 mg bolus, 20 min lock out)
Number of subjects: 50
Study 11465987 — intervention group
Group type: COMPARATOR
Intervention: Bolus (B-) group (no base rate, 1 mg bolus, 10 min lock out)
Number of subjects: 50
Study 11465987 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus-Continuous (BC-) group
Number of subjects: 50
Study 11465987 — intervention group
Group type: COMPARATOR
Intervention: Bolus (B-) group
Number of subjects: 50
Study 11465987 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 9596316 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal suctioning (TS)
Number of subjects: 13
Study 9596316 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled albuterol (500 microg) before suctioning
Number of subjects: 13
Study 7829838 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 202
Study 7829838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 3182163 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation with cognitive skill (PMR with Cl)
Number of subjects: 0
Study 3182163 — intervention group
Group type: COMPARATOR
Intervention: Active regeneration
Number of subjects: 0
Study 3182163 — intervention group
Group type: COMPARATOR
Intervention: Passive regeneration
Number of subjects: 0
Study 31806881 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol
Number of subjects: 108
Study 31806881 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 108
Study 31806881 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 108
Study 29757375 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based consent process
Number of subjects: 20
Study 29757375 — intervention group
Group type: COMPARATOR
Intervention: Paper-based consent process
Number of subjects: 20
Study 28043176 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart2HAART smartphone application
Number of subjects: 28
Study 28043176 — intervention group
Group type: COMPARATOR
Intervention: Control (directly observed treatment with adherence counseling alone)
Number of subjects: 28
Study 25200397 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry and regular medical review
Number of subjects: 238
Study 25200397 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 238
Study 23738992 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (depression care management)
Number of subjects: 1226
Study 23738992 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1226
Study 23738992 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor depression (both intervention and control)
Number of subjects: 1226
Study 22031267 — intervention group
Group type: COMPARATOR
Intervention: Myo-inositol (0.6 g in soft gel capsule or 2 g in powder)
Number of subjects: 0
Study 22031267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18452885 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 0.1, 0.2, 0.2, and 0.2 mg/kg
Number of subjects: 816
Study 18452885 — intervention group
Group type: COMPARATOR
Intervention: Albendazole 6.7 mg/kg
Number of subjects: 816
Study 17254459 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX‐A injection guided by electric stimulation
Number of subjects: 43
Study 17254459 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 43
Study 14675858 — intervention group
Group type: EXPERIMENTAL
Intervention: torasemide
Number of subjects: 237
Study 14675858 — intervention group
Group type: COMPARATOR
Intervention: furosemide
Number of subjects: 237
Study 14598357 — intervention group
Group type: EXPERIMENTAL
Intervention: rBPI(21)
Number of subjects: 18
Study 14598357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10456402 — intervention group
Group type: EXPERIMENTAL
Intervention: Bullectomy by VATS (n = 20)
Number of subjects: 38
Study 10456402 — intervention group
Group type: COMPARATOR
Intervention: Axillary thoracotomy (n = 18)
Number of subjects: 38
Study 9638217 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 18
Study 9638217 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 18
Study 2746644 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Self‐Management Training (CSM)
Number of subjects: 41
Study 2746644 — intervention group
Group type: COMPARATOR
Intervention: Attention Placebo Control
Number of subjects: 41
Study 2746644 — intervention group
Group type: COMPARATOR
Intervention: Current Clinic Conditions Control
Number of subjects: 41
Study 776582 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 7020
Study 776582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7020
Study 31496260 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C
Number of subjects: 69
Study 31496260 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C and intracameral bevacizumab
Number of subjects: 69
Study 31496260 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 69
Study 31300331 — intervention group
Group type: EXPERIMENTAL
Intervention: Four RTS,S/AS01 doses (four‐dose group)
Number of subjects: 3084
Study 31300331 — intervention group
Group type: EXPERIMENTAL
Intervention: Three RTS,S/AS01 doses (three‐dose group)
Number of subjects: 3084
Study 31300331 — intervention group
Group type: COMPARATOR
Intervention: Control group (four comparator doses)
Number of subjects: 3084
Study 28685283 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy flux density ESWT (Group A, n=20)
Number of subjects: 64
Study 28685283 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy flux density ESWT (Group B, n=21)
Number of subjects: 64
Study 28685283 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C, n=23)
Number of subjects: 64
Study 25909333 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric band (LAGB)
Number of subjects: 45
Study 25909333 — intervention group
Group type: COMPARATOR
Intervention: Intensive medical diabetes and weight management (IMWM)
Number of subjects: 45
Study 25909333 — intervention group
Group type: EXPERIMENTAL
Intervention: LAGB
Number of subjects: 45
Study 25909333 — intervention group
Group type: COMPARATOR
Intervention: IMWM
Number of subjects: 45
Study 25909333 — intervention group
Group type: EXPERIMENTAL
Intervention: LAGB and IMWM
Number of subjects: 45
Study 24002495 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 μg selenized yeast daily for 48 months)
Number of subjects: 1772
Study 24002495 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily for 48 months)
Number of subjects: 1772
Study 24002495 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 1772
Study 24002495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1772
Study 21148043 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasocitinib (100 mg)
Number of subjects: 60
Study 21148043 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg)
Number of subjects: 60
Study 21148043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19639398 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mm catheter tip
Number of subjects: 65
Study 19639398 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-mm catheter tip
Number of subjects: 65
Study 17352966 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure using wristbands (Sea-Band) for 5 days post-chemotherapy
Number of subjects: 36
Study 17352966 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acupressure)
Number of subjects: 36
Study 15162970 — intervention group
Group type: EXPERIMENTAL
Intervention: Female caregivers
Number of subjects: 868
Study 15162970 — intervention group
Group type: COMPARATOR
Intervention: Male caregivers
Number of subjects: 868
Study 11226090 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electrical stimulation (TAES) using ReliefBand device at P6 acupoint
Number of subjects: 221
Study 11226090 — intervention group
Group type: COMPARATOR
Intervention: Sham control (inactive device at P6 acupoint)
Number of subjects: 221
Study 11226090 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (inactive device at dorsal aspect of wrist)
Number of subjects: 221
Study 10097483 — intervention group
Group type: EXPERIMENTAL
Intervention: School and home-based drug prevention program
Number of subjects: 56
Study 10146667 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion program consisting of mailed health risk assessments, individualized reports, self-management materials, and quarterly newsletters.
Number of subjects: 0
Study 3042398 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 434
Study 3042398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 434
Study 31126960 — intervention group
Group type: EXPERIMENTAL
Intervention: Cy/GVAX+CRS-207 (Arm A)
Number of subjects: 213
Study 31126960 — intervention group
Group type: EXPERIMENTAL
Intervention: CRS-207 (Arm B)
Number of subjects: 213
Study 31126960 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (Arm C)
Number of subjects: 213
Study 27386808 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based telesupervising rehabilitation
Number of subjects: 0
Study 27386808 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 0
Study 26442399 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (D)
Number of subjects: 50
Study 26442399 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (S)
Number of subjects: 50
Study 23740211 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical spray (MedSpray™ tinea pedis 1% w/w)
Number of subjects: 120
Study 23740211 — intervention group
Group type: COMPARATOR
Intervention: Topical solution (Lamisil® Once 1% w/w)
Number of subjects: 120
Study 21041163 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam hydrochloride (3.75 g)
Number of subjects: 42
Study 21041163 — intervention group
Group type: COMPARATOR
Intervention: Cholestyramine (12 g)
Number of subjects: 42
Study 19247022 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein hernioplasty
Number of subjects: 99
Study 19247022 — intervention group
Group type: COMPARATOR
Intervention: Totally extraperitoneal laparoscopic hernioplasty (TEP)
Number of subjects: 99
Study 16898431 — intervention group
Group type: EXPERIMENTAL
Intervention: OASIS Mouth Moisturizing Spray
Number of subjects: 144
Study 16898431 — intervention group
Group type: COMPARATOR
Intervention: SALIVEZE (commercial control)
Number of subjects: 144
Study 15037411 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg; n = 18)
Number of subjects: 37
Study 15037411 — intervention group
Group type: COMPARATOR
Intervention: Continuous conjugated estrogens (0.625 mg) combined with medroxyprogesterone acetate (5 mg; n = 19)
Number of subjects: 37
Study 11816438 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether
Number of subjects: 1919
Study 11816438 — intervention group
Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 1919
Study 9387952 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized morphine 20 mg
Number of subjects: 16
Study 9387952 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized morphine 40 mg
Number of subjects: 16
Study 9387952 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 16
Study 8194940 — intervention group
Group type: EXPERIMENTAL
Intervention: Congruence Model intervention
Number of subjects: 40
Study 8194940 — intervention group
Group type: COMPARATOR
Intervention: Self-help groups
Number of subjects: 40
Study 8194940 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 3792081 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 15
Study 31759228 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery-enhanced interpretation training
Number of subjects: 0
Study 31759228 — intervention group
Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 0
Study 28094873 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine day activity program combined with WBV training (WBV at 30 Hz, 2‐mm peak‐to‐peak amplitude) for 9 weeks (18 sessions)
Number of subjects: 54
Study 28094873 — intervention group
Group type: COMPARATOR
Intervention: Routine program only without WBV for 9 weeks (18 sessions)
Number of subjects: 54
Study 28507187 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease activity indices (28‐joint Disease Activity Score, Clinical Disease Activity Index, Simplified Disease Activity Index)
Number of subjects: 462
Study 28507187 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain, physician's global assessment (PGA), and patient's global assessment (PtGA) of disease activity
Number of subjects: 462
Study 28507187 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 462
Study 28507187 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite disease activity indices, patient-reported pain and disease activity, physician-reported disease activity
Number of subjects: 462
Study 28507187 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical function, acute‐phase response, fatigue, participation, emotional well‐being
Number of subjects: 462
Study 26372507 — intervention group
Group type: EXPERIMENTAL
Intervention: WAVE-covered self-expandable metallic stents (WCS)
Number of subjects: 102
Study 26372507 — intervention group
Group type: COMPARATOR
Intervention: Uncovered self-expandable metallic stents (UCS)
Number of subjects: 102
Study 23421909 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of evidence-based infection control practices in ICUs
Number of subjects: 6
Study 23421909 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative outcomes on catheter-related bloodstream infections and performance indicators
Number of subjects: 6
Study 21459363 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid responders (RR; n = 41)
Number of subjects: 101
Study 21459363 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-rapid responders (non-RRs; n = 60)
Number of subjects: 101
Study 21459363 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT-RRs
Number of subjects: 101
Study 21459363 — intervention group
Group type: COMPARATOR
Intervention: ACGT-RRs
Number of subjects: 101
Study 21459363 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid responders (RRs)
Number of subjects: 101
Study 17999280 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention (II)
Number of subjects: 71
Study 17999280 — intervention group
Group type: COMPARATOR
Intervention: Self-help (SH)
Number of subjects: 71
Study 15135481 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound scissors (Group A, 45 patients)
Number of subjects: 92
Study 15135481 — intervention group
Group type: COMPARATOR
Intervention: No ultrasound scissors (Group B, 47 patients)
Number of subjects: 92
Study 12233274 — intervention group
Group type: EXPERIMENTAL
Intervention: OP-1 associated with osteosynthesis using a monolateral external fixator
Number of subjects: 0
Study 9824923 — intervention group
Group type: EXPERIMENTAL
Intervention: MABI and NBAS assessments
Number of subjects: 0
Study 9824923 — intervention group
Group type: COMPARATOR
Intervention: Control group (no participation in NBAS at delivery, written assessments at home)
Number of subjects: 0
Study 8133853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (900 mg/kg for 501-1000 g; 700 mg/kg for 1001-1500 g), repeated every 14 days until certain criteria were met
Number of subjects: 2416
Study 8133853 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo infusions during phase 1, none during phase 2)
Number of subjects: 2416
Study 8133853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin
Number of subjects: 2416
Study 8133853 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 2416
Study 2683557 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (40 mg t.i.d. for 28 days)
Number of subjects: 41
Study 2683557 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical tablets)
Number of subjects: 41
Study 31022099 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching and monetary incentives (Group A)
Number of subjects: 0
Study 31022099 — intervention group
Group type: COMPARATOR
Intervention: No health coaching and monetary incentives (Group B)
Number of subjects: 0